Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study

NCT03031821 is registered in ClinicalTrials.gov with Canadian Urologic Oncology Group as lead sponsor.

NCT NCT03031821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03031821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study
Lead sponsor
Canadian Urologic Oncology Group
Phase
Phase 3
Overall status
Terminated
Start date
July 12, 2018
Completion date
November 24, 2023
Enrollment
166 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic syndrome, prostate cancer